Neurotrophic activity of standardized extract of *Centella asiatica* ECa233 on human neuroblastoma cells.

Oraphan Wanakhachornkrai¹, Varisa Pongrakhananon², Preedakorn Chunhacha³, Aree Wanasuntronwong⁴, Anusara Vattanajun⁵, Boonyong Tantisira²,⁶, Pithi Chanvorachote²,³§, Mayuree H. Tantisira²,⁷#

¹Inter-disciplinary Program in Physiology, Graduate School, Chulalongkorn University, Bangkok, Thailand.

²Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.

³Cell-based Drug and Health Product Development Research Unit., Chulalongkorn University, Bangkok, Thailand.

⁴Faculty of Dentistry, Mahidol University, Bangkok, Thailand.

⁵Department of Physiology, Phramonkutklao College of Medicine, Bangkok, Thailand.

⁶Faculty of Pharmacy, Silpakorn University, Nakonprathom, Thailand.

⁷Faculty of Pharmaceutical Sciences, Burapha University, Chonburi, Thailand.

§Co-Corresponding author

# Corresponding author

E-mail address:

MHT: mayuree.t@chula.ac.th

PiC: pithi_chan@yahoo.com
OW: w_oraphan@hotmail.com
VP: iamrisa@gmail.com
PrC: preedakorn.chun@gmail.com
AW: naja787007@hotmail.com
AV: anusarav@hotmail.com
BT: t_boonyong@yahoo.com
Abstract

Background: In order to gain an insight into neuroprotective effects of ECa 233, a standardized extract of *Centella asiatica* previously reported in animal models of memory impairment induced by transient global ischemia or intracerebroventricular injection of β-amyloid, we aimed to investigate the effect of ECa 233 on neurite outgrowth of human IMR-32 neuroblastoma cell line.

Methods: Cells were seeded and incubated with various concentrations of ECa 233. Morphometric analysis was carried out by a measurement of the longest neurite growth of cells at 24 and 48 h. Contributing signaling pathways possibly involved were subsequently elucidated by western blot analysis.

Results: ECa 233, while had only limited effects on cell viability, significantly enhanced neurite outgrowth of IMR-32 cells at the concentrations of 1-100 µg/ml. Western blot analysis revealed that treatment of the cells with ECa 233 significantly up-regulated the level of activated ERK1/2 and Akt suggesting their involvement in the neurotrophic observed and subsequently verified by the finding that an addition of their respective inhibitors could reverse the effect of ECa 233 on these cells.

Conclusions: The present study clearly demonstrated neurite outgrowth promoting activity of ECa 233. ERK1/2 and Akt signaling pathways seemed to account for the neurotrophic observed. In conjunction with *in vivo* neuroprotective effect of ECa 233 previously reported, the results obtained support further development of ECa 233 for clinical use in neuronal injury or neurodegenerative diseases.

Keywords: Neurite outgrowth, *Centella asiatica*, ECa 233, ERK1/2, Akt, IMR-32 neuroblastoma
Background

Neurite outgrowth is an important initial step in the formation of neuronal network. Such neuronal behavior was also shown to implicate in neuronal regeneration and response to neural injury [1]. Mechanisms in regulation of neurite outgrowth have been intensively investigated and most accepted concept involves MEK/ERK and IP3K/Akt signaling pathways. Indeed, these molecular signals are triggered by tyrosine kinase receptor activation [2-6]. Several neurotrophic substrates to tyrosine kinase receptor such as nerve growth factor (NGF), brain derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3) have been identified [7, 8]. The activation of MEK/ERK and IP3K/Akt resulting in an increase in cell survival as well as an enhancement of neuronal growth and differentiation [9, 10]. Based on these contextuels, molecules or compounds that exhibit potent neurotropic activity are of great interest and may be useful for the treatment of stroke, brain or spinal cord injury and neurodegenerative diseases [11-13].

In search for potential neurotrophic activity from herbs acting on the central nervous system, the present study focused on the neurotrophic activity of Centella asiatica which has long time been claimed to be beneficial for managing disorders of the brain, skin and gastrointestinal tract [14]. Additionally, it was used as a brain booster for promoting brain growth and improving memory [12]. Like many other medicinal plants, C. asiatica contains several active compounds, including asiatic acid, madecasssic acid, asiaticoside, and madecassoside [15]. To avoid a large fluctuation in biological responses arising from variations of these bioactive constituents, we have established the standardized extract of C. asiatica, namely ECa 233. It is defined as a white to off-white extracted powder of C. asiatica containing triterpenoids not less than
80% and the ratio between madecassoside and asiaticoside was kept within 1.5± 0.5 [16]. Restorative and neuroprotective effects of ECa 233 have been demonstrated in animal models of learning and memory deficit induced by either a transient occlusion of common carotid arteries [17] or an intracerebroventricular injection of β-amyloid [18]. Protection of oxidative stress was proposed to be one of the possible underlying mechanisms. However, effect of ECa 233 on neurite outgrowth which could possibly be involved in its neurotrophic/neuroprotective effects has not yet been elucidated. Therefore, the present study aimed to investigate the effect of ECa 233 on the neurite growth and its underlying mechanisms in IMR-32 human neuroblastoma cells.

**Methods**

**Cell culture and reagents**

IMR-32 neuroblastoma cell was obtained from the American Type Culture Collection, ATCC (Manassas, VA, USA). Cells were cultured in DMEM/F12 supplemented with 10% fetal bovine serum. The 2 mmol/l L-glutamine and 100 units/ml penicillin/streptomycin in a 5% CO₂ at 37°C. BDNF, PD 098059, LY 294002 were purchased from Sigma Chemical. Inc. (St. Louis, MO, USA). Resazurin was purchased from Invitrogen (Carlsbad, CA, USA). Specific antibody for phospho-Akt, Akt, phospho-ERK1/2, ERK1/2 and GAPDH were purchased from Abcam (Cambridge, MA, USA), and peroxidase conjugated anti-rabbit secondary antibody were purchased from Cell Signaling (Danvers, MA, USA).

**Preparation of tested substances**

ECa 233 containing madecassoside 52% w/w and asiaticoside 32% w/w was kindly supplied by Associate Professor Ekarin Saifah and collaborators, Faculty of Pharmaceutical Sciences, Chulalongkorn University. Thailand. It was suspended in
sterile PBS at 10 mg/ml and served as stock solution. The stock solution was diluted to final concentration of 0.1, 1, 10 and 100 µg/ml. BDNF was dissolved in the sterile PBS at 50 µg/ml for stock solution. The stock solution was diluted to final concentration of 100 ng/ml. PD and LY were dissolved by DMSO and prepared into 10 µM/ml.

Cell viability assay

Cells were seeded in 96-well plates and incubated 24 h to allow the cells attachment and recover from passage by trypsinization. After incubation for 24 h, the plating media were removed and replaced. The cell were subsequently incubated for 30 minutes then subjected to treatments. After 24 h, cells were incubated with 1:50 resazurin at 37°C for 30 minutes. The well-plate was transferred to a fluorescence microplate reader with Softmax Pro software to measure fluorescence intensity of resorufin (resazurin product) at excitation wavelength of 530 nm and emission wavelength of 590 nm. The percentage of cell viability was calculated and compared with non-treated control. All analyses were performed for at least three independent triplicate experiments.

Measurement of neurite outgrowth

IMR-32 cells were cultured in a 96-well culture plate. After 24 h cells were subjected to indicated concentrations of ECa 233 (0.1, 1, 10, 100 µg/ml) and BDNF (100 ng/ml). A neurite was identified as a process equal to or longer than cell body diameter. The cells selected randomly from 3-4 fields of each well were photographed (phase contrast, Nikon, Inverted microscope ECLIPSE Ti-u) for morphometric analyses. The length of the longest neurite from each cell was measured using NIS-Element image software [19, 20].
To test the involvement of MEK and Akt pathway, their respective inhibitor (PD098059 for MEK and LY294002 for IP3K/Akt) was added 30 min prior to the test substance.

**Western blot analysis**

After specified treatments, cells were incubated in lysis buffer containing 20 mM Tris-HCl (pH 7.5), 1% TritonX-100, 150 mM sodium chloride, 10% glycerol, 1 mM sodium orthovanadate, 50 mM sodium fluoride, 100 nM phenylmethylsulfonyl fluoride, and a commercial protease inhibitor cocktail (Roche Molecular Biochemicals, Indianapolis, IN, USA) for 30 minutes on ice. Cell lysates were collected and centrifuged 12,000 rpm at 4°C, the supernatant was collected and determined for protein content using Bradford method (Bio-Rad, Hercules, CA, USA). Equal amount of proteins from each sample were denatured by heating at 95°C with laemmlli loading buffer for 5 min and were subsequently loaded onto 10% SDS-PAGE. After separation, proteins were transferred onto 0.45 µm nitrocellulose membranes (Bio-Rad). The transferred membranes were blocked in 5% non fat dry milk in TBST (25 mM Tris-HCl (pH 7.5), 125 mM NaCl, 0.1% tween20) for 1 h. Then washed with TBST and further incubated with the indicated primary antibodies at 4°C overnight. Membrane were washed twice with TBST for 10 min and incubated with secondary antibody for 1 h at room temperature. The immune complexes were detected by enhanced chemiluminescence substrate (Supersignal West Pico; Pierce, Rockford, IL, USA) and quantified using Image J software.

**Data analysis**

The results are expressed as mean ± S.D. or S.E. Simple comparison between two groups was performed using t-test. Comparison of data between groups was performed
using one-way ANOVA follow by Tukey’s post hoc test. \( P<0.05 \) was considered statistically significant.

Results

Effect of ECa 233 on viability of IMR-32 cells.

First, effect of ECa 233 on cell viability of IMR-32 cells was determined using Resazurin based assay. Cell were incubated in the presence or absence of ECa 233 (0.1, 1, 10 and 100 µg/ml) for 24 and 48 h and percentage of cell viability are determined. Percentage of such cell viability was compared among groups as well as with non-treated control (\( p<0.05 \)) (Fig 1). The results show that cell viability was 106±1.6, 95.6±6.44, 102.4±4.03 and 104.6±7.48 in response to ECa 233 at the concentrations of 0.1, 1, 10 and 100 µg/ml, respectively. In addition, cell viability at the 48 h after treatment in all ECa 233 treated groups showed no significant change from that of non-treated control indicating that treatment with ECa 233 at the concentrations tested had neither cytotoxic nor proliferative effects on these neuroblastoma cells.

Neurotrophic activity of ECa 233 on neurite outgrowth.

The non-cytotoxic and non-proliferative concentrations of ECa 233 at 0.1, 1, 10 and 100 µg/ml were further used in neurite outgrowth experiments. BDNF, a well-known trophic factor of neurite extension and neuronal survival was used as a positive control. We found that the addition of 100 ng/ml BDNF to the cells caused dramatic increase of the neurite outgrowth (Fig 2B). Likewise, cells treated with ECa 233 at the concentrations of 1, 10 and 100 µg/ml exhibited increased length of neurite compared to those of non-treated control (Fig 2D-F).
The morphometric analysis was carried out by measuring the longest neurite length of cell (Fig 3). After 24 and 48 h of treatment, the length of neurite obtained from cells treated with ECa 233 at the concentration of 0.1 µg/ml (23.02±1.05 and 26.46±0.87) was not significantly different from those of non-treated cells (26.22±1.19, 27.91±1.01). Whereas, neurite lengths exposed to ECa 233 at the concentrations of 1, 10 and 100 µg/ml were significantly enhanced in a time-dependent manner (35.58±2.61, 37.39±2.69 and 39.9±2.73 at 24 h, and 47.57±2.84, 44.03±1.66 and 46.52±2.71 at 48 h). Similar results were obtained when the cell were treated with BDNF 100 ng/ml (35.83±2.17 and 54.38±4.06). Notably, the effect of ECa 233 at 1, 10 and 100 µg/ml was comparable to that of BDNF with no significant difference.

Possible mechanisms of ECa 233-mediated neurotrophic activity

Effect of ECa 23 on ERK1/2 and Akt

In order to provide the possible mechanism of ECa 233-mediated neurite outgrowth observed in IMR-32 cells, western blot analysis was carried out to determine whether ERK and Akt signaling were involved. Cells were treated with ECa 233 and the level of phosphorylated ERK and phosphorylated Akt were determined. Figures 4A and B demonstrated that relative blot density of pERK/ERK and pAkt/Akt in response to ECa 233 at the concentration of 0.1 µg/ml was not different from those of non-treated group. However, ECa 233 at the concentrations of 1, 10 and 100 µg/ml significantly increased the level of phosphorylated ERK and phosphorylated Akt, suggesting that ECa 233 could possibly increase the neurite outgrowth via these 2 major pathways.

Effect of ECa 233 on neurite outgrowth in the presence of PD098059 and LY294002

Subsequently, the involvement of these two pathways in the neurite outgrowth promoting activity of ECa 233 was confirmed by an addition of specific inhibitors of
MEK (PD098059) and IP3K (LY294002) prior to the exposure to ECa 233. Addition of PD098059 or LY294002 caused a dramatic decrease of neurite extension of these cells (17.53±0.8 and 19.52±2.74, respectively) under the controlled experimental conditions. In comparison to neurite lengths of non-treated group which were 22.6±1.19 (Fig 5A), ECa 233 at the concentrations of 1, 10 and 100 µg/ml significantly enhanced the neurite outgrowth into 35.58±2.61, 37.39±2.69 and 39.9±2.73 respectively. Pretreatment of the cell with PD098059 significantly decreased the neurite outgrowth of the respective concentrations of ECa 233 into 17.14±1.06, 19.97±1.31 and 21.78±1.99. Similar results were demonstrated by LY294002 which significantly decreased the ECa 233-induced neurite outgrowth into 15.22±1.9, 16.7±1.1 and 17.6±1.45, respectively.

Discussion

Although the plant originated extracts have garnered attentions as important sources of drugs and health products, the inconsistency of main components found in such extracts limited their use as well as further development to clinical use. Establishment of standardized extract with consistency of its bioactive constituents could enhance reproducible biological responses and subsequently reliable use of herbal products [21]. Based on well-defined constituents and numbers of scientific evidence, EGb 761, a standardized extract of Chinese ancient plant, Ginko biloba, known as a brain tonic remedy, has been prescribed for memory deficit all over the world [22]. By the same analogy, C. asiatica which has long been used in Ayurveda to enhance memory was extensively investigated [23]. In an attempt to make a reliable herbal product, ECa 233, a standardized extract of C. asiatica, was established and being investigated for its effect on brain function. We have found that ECa 233 could attenuate memory deficit and exerted anxiolytic effect in animal models [16-18].
administration of fresh leaf juice of *C. asiatica* was found to enhance dendritic aborization of hippocampal and amygdala neurons in neonatal and adult rats [24-27], we hypothesized that ECa 233 might enhance neurite outgrowth.

As expected, the present study clearly demonstrated neurotrophic effect of ECa 233 in the range of 1-100 μg/ml. There are numerous signaling involving in neurite outgrowth. Among them, ERK and Akt activations are long known to be important for neurite elongation induced by certain neurotrophic factors including NGF [28, 29], neurotrophin-3 (NT-3) [30], BDNF [31] as well as natural compounds including FK506 [32, 33], genipin [34], honokiol [4] and militarinone A [9]. In addition, ginsenoside, triterpenoidglycoside from gingseng, has been shown to significantly increase the neurite outgrowth of neuroblastoma cells [35].

In line with the results of natural products mentioned above, western blot analysis showing that administration of ECa 233 significantly increased the level of phosphorylated ERK and Akt in IMR-32 cells. Asiatic acid, one of chemical constituents present in *C. asiatica* has been proposed to elicit its effect via this MAP kinase pathway [12]. However, the results observed in the present study are likely to be attributable to madecassoside and/or asiaticoside, the major constituents of ECa 233. This notion was later confirmed by the results that neurite outgrowth promoting effect of ECa 233 was hindered by specific inhibitors of MEK (PD098059) or IP3K (LY294002) suggesting that ECa 233 promotes neurite outgrowth in human neuroblastoma IMR-32 cells via MEK/ERK and IP3K/Akt-dependent mechanisms.

Interestingly, ECa 233 in the concentrations that promotes neurite outgrowth in human neuroblastoma IMR-32 cells had no effect on cell viability under the experimental condition indicating safety of ECa 233, a standardized extract derived
from *C. asiatica* which is widely consumed as food. In addition, safety profiles of ECa 233 have been reported in both acute and sub-chronic toxicity testing. Oral administration of ECa 233 in the dose up to 10 g/kg did not cause any lethality and no significant adverse effects was observed in experimental animals receiving daily administration of ECa 233 in the dose range of 10-1000 mg/kg/day [36]. In consideration to the very favorable safety profiles and *in vivo* neuroprotective activity of ECa 233, the results of the present study supports further development of ECa 233 for neuronal injury as well as neurodegenerative diseases in human.

**Conclusions**

The present study demonstrated the neurite outgrowth promoting activity of ECa 233 in human IMR-32 neuroblastoma cell line. The neurotrophic observed seemed to be mediated via ERK1/2 and Akt signaling pathways. The results obtained support potential benefit of ECa 233 for neuronal injury and neurodegenerative diseases. Further pharmacodynamic and pharmacokinetic studies of ECa 233 are needed to bring ECa 233 into clinical use.

**List of abbreviations**

*C. asiatica: Centella asiatica; MEK: mitogen activated protein kinase; ERK: extracellular signaling regulated kinase; IP3K: inositol 1,4,5-triphosphate 3-kinase; NGF: nerve growth factor; BDNF: brain derived neurotrophic factor; NT-3: neurotrophin-3; PD: PD 098059; LY: LY 294002**

**Competing interests**

All authors declare that they have no competing interests.
Authors' contributions

OW participated in design and conducting the experiments, analysis of data, drafting the manuscript. VP, PrC and AW participated in technical supports and interpretation of the data. AV and BT supervised, design of experiments, analyzed and interpretation of the data. PiC was a coordinator, designed the study, analysis and interpretation of data, and drafting the manuscript. MT supervised, conceived and designed the experiment, interpretation of the data and revision of the manuscript. All authors have read and approved the final manuscript.

Acknowledgements

The work was supported by The 90th Anniversary of Chulalongkorn University Fund (Ratchadaphiseksomphot Endowment Fund) and Ratchadaphiseksomphot Endowment Fund for Cell-based Drug and Health Product Development Research Unit. The authors would like to thank Associate Professor Ekarin Saifah and collaborates for the provision of ECa 233.
References


15. Inamdar PK, Yeole RD, Ghogare AB, de Souza NJ: **Determination of biologically active constituents in Centella asiatica. J Chromatography A** 1996, **742**: 127-130


18. Kam-eg A, Tantisira B, Tantisira MH: **Preliminary study on effects of standardized extract of Centella asiatica, Eca 233, on deficit of learning and memory induced by an intracerebroventricular injection of β-amylloid peptide in mice. Thai J Pharmacol** 2009, **31**: 79-82.


29. Tsuji M, Inanami O, Kuwabara M: Induction of neurite outgrowth in PC12 cells by alpha-phenyl-N-tert-butylnitron through activation of protein kinase C and the


36. Chivapat S, Chavalittumrong P, Tantisira MH: Acute and sub chronic toxicity studies of a standardized extract of *Centella asiatica* ECa **233**. *Thai J Pharm Sci* 2011, **35**: 55-64.
Figure legends

**Figure 1.** Effects of ECa 233 on cell viability and proliferation of IMR-32 cells at 24 and 48 h. after applying. There was no significant difference among groups.

**Figure 2.** Representative photomicrograph of IMR-32 cells using phase contrast (A) non-treated control, (B) BDNF 100 ng/ml, (C-F) ECa 233 0.1, 1, 10 and 100 µg/ml respectively (scale bar = 50 µm). Cells treated with BDNF and ECa 233 at the concentrations of 1, 10 and 100 µg/ml showed relatively longer neurite length.

**Figure 3.** Morphometric analysis of IMR-32 cells affected by ECa 233. After cells cultured for 24 and 48 h in the presence of either ECa 233 (0.1, 1, 10 and 100 µg/ml) or BDNF (100 ng/ml). Morphometric analysis was carried out. Average of the neurite length was significantly increased after being treated with ECa 233 (1, 10 and 100 µg/ml) or BDNF. The data presented as mean ± S.E., ** = p<0.01, *** = p<0.001 vs non treated control.

**Figure 4.** Relative blot density of pERK/ERK and pAkt/Akt in response to ECa 233 treatment (A) ERK1/2 and ERK1/2 phosphorylation (B) Akt and Akt phosphorylation.
The level of phospho-ERK1/2 and phospho-Akt in IMR-32 cells after treated with ECa 233 (1, 10 and 100 µg/ml) were significantly higher when compared with control. Densitometric analysis of the indicated proteins normalized with the density of GAPDH band were plated and presented as mean ± S.D. of three independent experiments, * = p< 0.05, ** = p< 0.001 vs non treated control.

**Figure 5.** Representative photomicrograph of IMR-32 cells (A) after pre-treated with LY294002 or PD098059 in the presence or absence of ECa 233 (1, 10 and 100 µg/ml) (scale bar = 50 µm). (B) Morphometric analysis of the cell treated with LY294002 or PD098059 on the increment of neurite outgrowth induced by ECa 233. Data are presented as mean ± S.E., * = p< 0.05, ** = p< 0.001 vs non treated control. ### = p< 0.001 vs ECa 233 treated groups.
Figure 3

Average of the neurite length (µm)

24h

<table>
<thead>
<tr>
<th>ECa233 (µg/ml)</th>
<th>0</th>
<th>0.1</th>
<th>1</th>
<th>10</th>
<th>100</th>
</tr>
</thead>
<tbody>
<tr>
<td>BDNF 100ng/ml</td>
<td>20</td>
<td>15</td>
<td>10</td>
<td>20</td>
<td>25</td>
</tr>
</tbody>
</table>

48h

<table>
<thead>
<tr>
<th>ECa233 (µg/ml)</th>
<th>0</th>
<th>0.1</th>
<th>1</th>
<th>10</th>
<th>100</th>
</tr>
</thead>
<tbody>
<tr>
<td>BDNF 100ng/ml</td>
<td>20</td>
<td>15</td>
<td>10</td>
<td>20</td>
<td>25</td>
</tr>
</tbody>
</table>
Figure 4
Figure 5

(A) Graphical representation of cellular response to ECa233.

(B) Bar graph showing the average of neurite length under different conditions.

Legend:
- LY (10μM)
- PD (10μM)

Statistical significance:
- *: p < 0.05
- **: p < 0.01
- ***: p < 0.001